(Q45395361)

English

Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia

scientific article published on 29 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia (English)

1 reference

Europe PubMed Central

14 December 2017

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Mitsutaka Nishimoto

1

1 reference

Europe PubMed Central

14 December 2017

Hirohisa Nakamae

2

1 reference

Europe PubMed Central

14 December 2017

Ki-Ryang Koh

3

1 reference

Europe PubMed Central

14 December 2017

Saori Kosaka

4

1 reference

Europe PubMed Central

14 December 2017

Kana Matsumoto

5

1 reference

Europe PubMed Central

14 December 2017

Kunihiko Morita

6

1 reference

Europe PubMed Central

14 December 2017

Hideo Koh

7

1 reference

Europe PubMed Central

14 December 2017

Takahiko Nakane

8

1 reference

Europe PubMed Central

14 December 2017

Masahiko Ohsawa

9

1 reference

Europe PubMed Central

14 December 2017

Masayuki Hino

10

1 reference

Europe PubMed Central

14 December 2017

publication date

29 March 2013

1 reference

Europe PubMed Central

14 December 2017

Acta Haematologica

1 reference

Europe PubMed Central

14 December 2017

130

1 reference

Europe PubMed Central

14 December 2017

2

1 reference

Europe PubMed Central

14 December 2017

111-114

1 reference

Europe PubMed Central

14 December 2017

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Low concentrations of STI571 in the cerebrospinal fluid: a case report

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Central nervous system involvement in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1159%2F000347158

21 January 2018

Identifiers

10.1159/000347158

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45395361&oldid=2076543135"